In support of this, several meta-analyses have shown that SOX2 expression in non–small cell lung cancer (NSCLC) and esophageal squamous cell carcinoma (ESCC) correlates with better survival outcomes [49,50,51]. Here, SOX2 is linked to esophageal squamous cell carcinoma.